Good news!
"... What’s new: Pharma giant Eli Lilly agreed to give as much as $2.75 billion to Insilico Medicine, a Hong Kong-based biotechnology company that applies generative AI across its drug-discovery pipeline.
Initially, Lilly will pay $115 million for exclusive rights to develop and sell undisclosed drugs that have not yet been tested in humans, while further payments will be tied to developmental, regulatory, and commercial milestones ...
This is the third agreement between the companies following an AI software license in 2023 and a $100 million research collaboration in November 2025.
AI drug-discovery: Founded in 2014, Insilico has used AI to develop 28 candidate drugs, roughly half of which are in clinical trials.
The most advanced one, Rentosertib, targets idiopathic pulmonary fibrosis (IPF), a disease in which scarring progressively reduces lung function. A Phase 2a trial (an early, small-scale test of efficacy) showed positive results.
A second drug, Garutadustat, which is intended to treat inflammatory bowel disease, entered Phase 2a in January 2026. ...
Insilico’s pipeline suggests generative AI can tackle one of the hardest problems in science: finding a molecule that binds to a particular protein, is absorbed by the body, isn’t toxic, and helps patients. ..."
Insilico Medicine pipeline
No comments:
Post a Comment